Skip to main content
. 2019 Aug 7;18(4):3914–3924. doi: 10.3892/ol.2019.10731

Figure 2.

Figure 2.

The percentage of CD8+ T cells and CTLA-4 expression on CD8+ T cells in gBRCAm and BRCAwt HGSOC (Cohort 1). (A) There was no difference between the percentage of CD8+ T cells in gBRCAm carriers compared to BRCAwt (P=0.089). (B and C) The percentage of CD8+ T cells was higher in gBRCAm carriers <5 years from initial diagnosis (P=0.031) but this difference did not persist in gBRCAm carriers ≥5 years from initial diagnosis (P=0.97). (D) CTLA-4 expression among CD8+ T cells was significantly higher in patients with HGSOC with gBRCAm compared with patients with BRCAwt (P=0.0073). (E and F) This difference was sustained in gBRCAm carriers ≥5 years from initial diagnosis (P=0.0016), but not in gBRCAm carriers <5 years from initial diagnosis (P=0.12). The dotted lines represent the median values. CTLA-4, cytotoxic T lymphocyte-associated protein 4; gBRCAm, germline BRCA mutation; BRCAwt, germline BRCA wild-type; HGSOC, high grade serous ovarian carcinoma; MFI, median fluorescence intensity.